Seres Therapeutics, Inc., announced the initiation of two academic research collaborations to further develop the company’s microbiome therapeutics platform as a treatment for inflammatory bowel disease (IBD).
Under the agreements, the company will work with teams at the Research Institute of St. Joseph’s Hamilton, Canada, and the Medical University of Graz, Austria.
In this NewYork-Presbyterian Hospital video, learn more about how these bacteria may affect the body, especially in inflammatory bowel diseases (IBD) patients with Dr. Randy Longman, physician-researcher at the Center for Advanced Digestive Care (CADC) at NewYork-Presbyterian/Weill Cornell Medical Center.
IBD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.